Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6094 in Papillary Renal Cell Carcinoma
NCT02127710Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of savolitinib in papillary renal cell carcinoma (PRCC), sponsored by AstraZeneca. Started Apr 2014; status: completed.
02
Drugs
savolitinib
03
Conditions
papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on NCT02127710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02127710.